Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Tschan

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 13, 2023
Albumin-Binding and Conventional PSMA Ligands in Combination with <sup>161</sup>Tb: Biodistribution, Dosimetry, and Preclinical TherapyViviane J Tschan, Sarah D Busslinger, Peter Bernhardt, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 29, 2019
Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancerCristina Müller, Christoph A Umbricht, Nadezda Gracheva, et al.
NPJ Precision Oncology|November 3, 2023
Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancerMichele Garioni, Viviane J Tschan, Lauriane Blukacz, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 5, 2024
First-in-human administration of [<sup>161</sup>Tb]Tb-SibuDAB and comparative dosimetry with standard [<sup>177</sup>Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia studyAlin Chirindel, Guillaume P Nicolas, Frida Westerbergh, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 13, 2023
Albumin-Binding and Conventional PSMA Ligands in Combination with <sup>161</sup>Tb: Biodistribution, Dosimetry, and Preclinical TherapyViviane J Tschan, Sarah D Busslinger, Peter Bernhardt, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 29, 2019
Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancerCristina Müller, Christoph A Umbricht, Nadezda Gracheva, et al.
NPJ Precision Oncology|November 3, 2023
Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancerMichele Garioni, Viviane J Tschan, Lauriane Blukacz, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 5, 2024
First-in-human administration of [<sup>161</sup>Tb]Tb-SibuDAB and comparative dosimetry with standard [<sup>177</sup>Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia studyAlin Chirindel, Guillaume P Nicolas, Frida Westerbergh, et al.
Pageof 2